



## **NextPharma Technologies Appoints New Management Team at its Manufacturing Facility in San Diego, North America**

Surrey, UK, 8th February 2010 - NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that it has appointed a new management team at its San Diego facility in California, North America.

Ronald W. Collins has been appointed as **Interim General Manager**. Ron has many years of experience, including building up a steriles formulation development and fill-finish manufacturing business for clinical trials supply, running a global technology company and serving as vice president of a Fortune 500 company.

Alan Sanders has been appointed as **Director of Finance**. Alan is an accomplished, finance professional and operations director with twenty years of progressive and results oriented experience in financial planning, analysis and reporting, demand planning, price setting, manufacturing costing, management controls, G/L maintenance, cash and risk management, SOX compliance, and operations management in a global environment.

Mary Richardson has been appointed as **Director of Quality** and comes with many years experience of QA and compliance management. Mary has a degree in microbiology, twenty-seven years of pharmaceutical and biotechnology experience and is licensed by the California State Board of Pharmacy and Mary is an ASQ Certified Quality Engineer and Certified Quality Auditor.

Completing the management team is Bruce Johnson, **Director of Operations**. Bruce's track record in sterile biologics manufacturing and lyophilization demonstrates his strong leadership, team building and hands-on management skills. Bruce has twenty one years of sterile pharmaceutical manufacturing and lyophilization experience.

This new team at NextPharma will be responsible for the day-to-day management of the facility in San Diego and for continuing to build the company's presence in the United States through the further development of sterile manufacturing of investigational new products, diagnostics and devices, clinical trials labeling and packaging and long term storage and distribution.

Sean Marett, Managing Director NextPharma Technologies, Product Development Services, commented: "We are delighted to have this team in place in San Diego. Collectively they bring a wealth of knowledge and experience in sterile manufacturing of investigational medical products and devices and we look forward to the future as they continue to establish NextPharma Technologies as a leading contract manufacturing provider in North America".

NextPharma's North American facility based in San Diego, California, serves small to large corporations world wide in the biotechnology, pharmaceutical, diagnostic, and medical device industries. Its aseptic area has multiple clean room suites offering Class 10,000 (Class 7 or Class C) formulation rooms and Class 100 (Class 5 or Class A) filling hoods or rooms. This facility is FDA licensed for drugs and medical devices and ISO 13485:2003 certified for medical device manufacturing. NextPharma San Diego's Class 5 clean room is equipped with a 48 sq ft Hull lyophilizer which is capable of drying 6,500 5mL vials and its external condenser can sublime 45L of water.

This facility also provides Clinical Trial Services including randomization double-blinding, generation of emergency letters, packaging, kitting, labeling (Phase I – Phase IV studies), cold-chain storage, distribution, return accountability and destruction.

NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.

-Ends-

**Contact:**

**Bill Wedlake**

Chief Executive Officer,  
NextPharma Technologies Holding Limited  
Connaught House,  
Portsmouth Road,  
Send,  
Surrey, GU27 7JY, UK  
Tel +44 (0) 1483 479 121  
[www.nextpharma.com](http://www.nextpharma.com)

**Ron Collins**

Interim General Manager  
Bioserv Corp d/b/a/ NextPharma Technologies  
5340 Eastgate Mall, San Diego, CA 92121  
Tel +1 (858) 450 3123,  
email: [ron.collins@nextpharma-us.com](mailto:ron.collins@nextpharma-us.com)  
web site: [www.nextpharma.com](http://www.nextpharma.com)

**Notes to Editors:**

**About NextPharma**

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.

We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture. NextPharma offers 'one-stop' logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.

We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.

We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.

We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.

All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.